Reasons for treating secondary AML as de novo AML-Reference-Cited by-同舟云学术

Reasons for treating secondary AML as de novo AML

Published:2010-08-12 Issue:3 Volume:85 Page:217-226
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Østgård Lene Sofie Granfeldt,Kjeldsen Eigil,Holm Mette Skov,Brown Peter De Nully,Pedersen Bjarne Bach,Bendix Knud,Johansen Preben,Kristensen Jørgen Schøler,Nørgaard Jan Maxwell

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2010.01464.x/fullpdf

Reference33 articles.

1. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia;Kalaycio;Am J Hematol,2008

2. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning;Grigg;Biol Blood Marrow Transplant,2007

3. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG;Braess;Blood,2009

4. Age and acute myeloid leukemia;Appelbaum;Blood,2006

5. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome;Gajewski;J Clin Oncol,1989

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France;Cancer Medicine;2023-08

2. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry;Haematologica;2023-05-18

3. Updates in molecular genetics of therapy-related myeloid neoplasms;Seminars in Diagnostic Pathology;2023-05

4. Dual inhibition of EZH2 and G9A/GLP histone methyltransferases by HKMTI-1-005 promotes differentiation of acute myeloid leukemia cells;Frontiers in Cell and Developmental Biology;2023-03-23

5. Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population‐based study in France;Cancer Medicine;2023-01-29